Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26966728 | 1.00 | CHRM1 (0.56) | CHRM1ALDH1A1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL26966604 | 1.00 | CHRM1 (0.56) | CHRM1ALDH1A1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL26966636 | 0.88 | CHRM1 (0.51) | CHRM1ALDH1A1MEN1KMT2A | |
| SCHEMBL30671905 | 0.88 | CHRM1 (0.51) | CHRM1ALDH1A1MEN1KMT2A | |
| SCHEMBL27120319 | 0.88 | CHRM1 (0.51) | CHRM1ALDH1A1MEN1KMT2A | |
| SCHEMBL26966578 | 0.88 | CHRM1 (0.51) | CHRM1ALDH1A1MEN1KMT2A | |
| SCHEMBL30671907 | 0.88 | CHRM1 (0.51) | CHRM1ALDH1A1MEN1KMT2A | |
| SCHEMBL26966615 | 0.87 | CHRM1 (0.57) | CHRM1 | |
| SCHEMBL26966575 | 0.81 | CHRM1 (0.73) | CHRM1 | |
| SCHEMBL23672924 | 0.81 | CHRM1 (0.49) | CHRM1ALDH1A1RAB9ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851406-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2023-12-26 | — | — | US | claimed |
| US-11851406-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2023-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851406-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885ALDH1A1 3782/4885RAB9A 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.